Ongoing Development. The Parties acknowledge and agree that additional Development will be required to obtain Regulatory Approvals for the Licensed Products in the Territory. After the Effective Date, Xynomic shall be solely responsible for, and has full decisional power with respect to, Development of the Licensed Products in the Territory, subject to Pharmacyclics’ obligation to wind up and close all clinical trials which were sponsored by Pharmacyclics prior to the Effective Date.
Appears in 3 contracts
Sources: License Agreement (Bison Capital Acquisition Corp.), License Agreement (Bison Capital Acquisition Corp.), License Agreement (Bison Capital Acquisition Corp.)